Destina Chemistry

Enabling the routine use of miRNAs in drug development and clinical diagnostics

miRNA detection using immunoassay workflows & platforms

Single-Well Multi-Omic

(miRNA + Protein)

Solves PCR Bias through detection of all isomiRs

PLATFORM AGNOSTIC:

VALIDATED ON MULTIPLE PLATFORMS

Expands utility & menu of existing platforms

PROVIDES NEW OPPORTUNITIES FOR IMPACTFUL ASSAYS

MicroRNAs are powerful early disease biomarkers, but their adoption in drug development and diagnostic settings has been limited by instability, isomiR detection complexity with PCR-based methods, and inconsistent published results. Our patented Chemistry overcomes the barriers, creating a definitive strategic bridge between research and clinical practice.

First Implementation Case: LiverAce™ Kits

Validated multi-omic assays for early hepatotoxicity testing in drug development and clinical trials.

For Research Use Only

Not for use in diagnostic procedures

Projected regulatory clearance in 2027

LiverAce™ COMBO Kit

Simultaneous quantification of miR-122 and CK18 in a single reaction. Provides biological depth and data integrity.

Explore Assay →

LiverAce™ SinglePlex Kit

Rapid, PCR-free miR-122 testing. Absolute isomiR resolution for accurate toxicity assessment.

Explore Assay →

Data-Driven Insights

Visualizing the DGL-Tech advantage in molecular stability and diagnostic resolution.

RNA Stabilization Solution

Click for Research Details →

isomiR Precision & Bias

Click for Research Details →

Diagnostic Sensitivity

Click for Research Details →

Transform Your Analytical Capabilities

Connect with our specialists to purchase kits or to explore technology licensing and custom assays for your miRNA/proteins of interest

Get in Touch